Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 297 articles:
HTML format
Text format



Single Articles


    June 2017
  1. CHAOUI D, Choquet S, Sanhes L, Mahe B, et al
    Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.
    Leuk Lymphoma. 2017;58:1366-1375.
    PubMed     Text format     Abstract available


  2. HANDUNNETTI SM, Polliack A, Tam CS
    Microvesicles in chronic lymphocytic leukemia: ready for prime time in the clinic?
    Leuk Lymphoma. 2017;58:1281-1282.
    PubMed     Text format    


    May 2017
  3. BUTTNER B, Knoth H, Kramer M, Oertel R, et al
    Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 16:1-10. doi: 10.1080/10428194.2017.1319051.
    PubMed     Text format     Abstract available


  4. TANOUE S, Konuma T, Takahashi S, Watanabe E, et al
    Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome.
    Leuk Lymphoma. 2017 May 16:1-3. doi: 10.1080/10428194.2017.1318440.
    PubMed     Text format    


  5. CAMPREGHER PV, Halley NDS, Vieira GA, Fernandes JF, et al
    Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1318437.
    PubMed     Text format    


  6. OWEN C, Christofides A, Johnson N, Lawrence T, et al
    Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 16:1-9. doi: 10.1080/10428194.2017.1318439.
    PubMed     Text format     Abstract available


  7. BUSCA A, Lessi F, Verga L, Candoni A, et al
    SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Leuk Lymphoma. 2017 May 16:1-6. doi: 10.1080/10428194.2017.1318438.
    PubMed     Text format     Abstract available


  8. OKABE S, Tauchi T, Tanaka Y, Ohyashiki K, et al
    Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.
    Leuk Lymphoma. 2017 May 15:1-3. doi: 10.1080/10428194.2017.1312373.
    PubMed     Text format    


  9. ZHAO B, Bhattacharya S, Yu Q, Fuchs SY, et al
    Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.
    Leuk Lymphoma. 2017 May 15:1-7. doi: 10.1080/10428194.2017.1319053.
    PubMed     Text format     Abstract available


  10. SHANMUGANATHAN N, Hiwase DK, Ross DM
    Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312377.
    PubMed     Text format     Abstract available


  11. AW A, Brown JR
    The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 9:1-11. doi: 10.1080/10428194.2017.1312387.
    PubMed     Text format     Abstract available


  12. COLOMER-LAHIGUERA S, Pisecker M, Konig M, Nebral K, et al
    MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
    Leuk Lymphoma. 2017 May 9:1-10. doi: 10.1080/10428194.2017.1312383.
    PubMed     Text format     Abstract available


  13. BUTLER JS, Qiu YH, Zhang N, Yoo SY, et al
    Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.
    Leuk Lymphoma. 2017;58:1207-1218.
    PubMed     Text format     Abstract available


    April 2017
  14. LIU H, Zhang J, Ren S, Chen M, et al
    Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
    Leuk Lymphoma. 2017 Apr 13:1-4. doi: 10.1080/10428194.2017.1312378.
    PubMed     Text format    


  15. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Text format     Abstract available


  16. SANNA M, Caocci G, Ledda A, Orru F, et al
    Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Apr 12:1-10. doi: 10.1080/10428194.2017.1312666.
    PubMed     Text format     Abstract available


  17. BOSCH R, Mora A, Vicente EP, Ferrer G, et al
    FcgammaRIIb expression in early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Apr 4:1-7. doi: 10.1080/10428194.2017.1307981.
    PubMed     Text format     Abstract available


  18. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Text format     Abstract available


  19. HARIVENKATESH N, Kumar L, Bakhshi S, Sharma A, et al
    Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Leuk Lymphoma. 2017 Apr 3:1-9. doi: 10.1080/10428194.2017.1287359.
    PubMed     Text format     Abstract available


  20. ROBESOVA B, Jeziskova I, Krejci M, Mayer J, et al
    Genesis of new allele at locus D2S1360 in leukemia patient.
    Leuk Lymphoma. 2017 Apr 3:1-4. doi: 10.1080/10428194.2017.1307363.
    PubMed     Text format    


    March 2017
  21. RAFELSON WM, Reagan JL, Fast LD, Lim SH, et al
    Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
    Leuk Lymphoma. 2017 Mar 28:1-9. doi: 10.1080/10428194.2017.1306646.
    PubMed     Text format     Abstract available


  22. CHEN X, Othus M, Wood BL, Walter RB, et al
    Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307359.
    PubMed     Text format    


  23. HEISEL RW, Sutton RR, Mascara GP, Winger DG, et al
    Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
    Leuk Lymphoma. 2017 Mar 28:1-8. doi: 10.1080/10428194.2017.1306645.
    PubMed     Text format     Abstract available


  24. KO DR, Jang JE, Chung SP, Lee JW, et al
    Usefulness of the delta neutrophil index as an ancillary test in the emergency department for the early diagnosis of suspected acute promyelocytic leukemia.
    Leuk Lymphoma. 2017 Mar 2:1-8. doi: 10.1080/10428194.2017.1296142.
    PubMed     Text format     Abstract available


  25. DARAKI A, Zachaki S, Rosmaraki F, Kalomoiraki M, et al
    Association of GSTP1 inactivating polymorphism with acute myeloid leukemia and its specific chromosomal abnormalities.
    Leuk Lymphoma. 2017 Mar 2:1-3. doi: 10.1080/10428194.2017.1295148.
    PubMed     Text format    


    February 2017
  26. OKA S, Ono K, Nohgawa M
    Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
    Leuk Lymphoma. 2017 Feb 28:1-3. doi: 10.1080/10428194.2017.1295146.
    PubMed     Text format    


  27. ESKAZAN AE
    Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Feb 28:1-2. doi: 10.1080/10428194.2017.1295145.
    PubMed     Text format    


  28. VILIA MG, Fonte E, Veliz Rodriguez T, Tocchetti M, et al
    The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Feb 28:1-7. doi: 10.1080/10428194.2017.1295142.
    PubMed     Text format     Abstract available


  29. ISKIERKA-JAZDZEWSKA E, Hus M, Giannopoulos K, Madro E, et al
    Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
    Leuk Lymphoma. 2017 Feb 28:1-4. doi: 10.1080/10428194.2017.1292353.
    PubMed     Text format    


  30. ORGEL E, Mueske NM, Sposto R, Gilsanz V, et al
    A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Feb 20:1-9. doi: 10.1080/10428194.2017.1289526.
    PubMed     Text format     Abstract available


  31. KHAN N, Hantel A, Knoebel RW, Artz A, et al
    Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 Feb 20:1-7. doi: 10.1080/10428194.2017.1289524.
    PubMed     Text format     Abstract available


  32. THOMAS JS, Jagasia M, Vnencak-Jones CL
    Comparison of BCR/ABL1 mRNA levels by quantitative real-time PCR in peripheral blood and bone marrow specimens of patients with chronic myelogenous leukemia.
    Leuk Lymphoma. 2017 Feb 14:1-4. doi: 10.1080/10428194.2017.1287362.
    PubMed     Text format    


  33. XIA D, Zhang YT, Xu GP, Yan WW, et al
    Sertraline exerts its antitumor functions through both apoptosis and autophagy pathways in acute myeloid leukemia cells.
    Leuk Lymphoma. 2017 Feb 13:1-10. doi: 10.1080/10428194.2017.1287358.
    PubMed     Text format     Abstract available


  34. MU Q, Guo L, Hu Y, Sheng L, et al
    SNX2-ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis.
    Leuk Lymphoma. 2017 Feb 9:1-3. doi: 10.1080/10428194.2017.1287357.
    PubMed     Text format    


  35. MAITI A, Cortes J, Ferrajoli A, Estrov Z, et al
    Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Feb 9:1-6. doi: 10.1080/10428194.2017.1283030.
    PubMed     Text format    


  36. VOJDEMAN FJ, Herman SE, Kirkby N, Wiestner A, et al
    Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Feb 7:1-7. doi: 10.1080/10428194.2017.1285027.
    PubMed     Text format     Abstract available


  37. REBECHI MT, Pratz KW
    Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.
    Leuk Lymphoma. 2017 Feb 6:1-11. doi: 10.1080/10428194.2017.1283031.
    PubMed     Text format     Abstract available


    January 2017
  38. NAGEL S, Pommerenke C, Meyer C, Kaufmann M, et al
    Identification of a tumor suppressor network in T-cell leukemia.
    Leuk Lymphoma. 2017 Jan 31:1-15. doi: 10.1080/10428194.2017.1283029.
    PubMed     Text format     Abstract available


  39. KRULL K, Kunstreich M, Klasen-Sansone J, Kloetgen A, et al
    Osteonecrosis develops independently from radiological leukemic infiltration of bone in adolescents with acute lymphoblastic leukemia - first findings of the OPAL trial.
    Leuk Lymphoma. 2017 Jan 31:1-10. doi: 10.1080/10428194.2017.1280605.
    PubMed     Text format     Abstract available


  40. LOEFF FC, van Egmond HM, Nijmeijer BA, Falkenburg JH, et al
    Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
    Leuk Lymphoma. 2017 Jan 31:1-14. doi: 10.1080/10428194.2017.1281411.
    PubMed     Text format     Abstract available


  41. NAN X, Qin Q, Gentille C, Ensor J, et al
    Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center.
    Leuk Lymphoma. 2017 Jan 31:1-11. doi: 10.1080/10428194.2016.1277386.
    PubMed     Text format     Abstract available


  42. CHANG YC, Lo WJ, Huang YT, Lin CL, et al
    Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
    Leuk Lymphoma. 2017 Jan 31:1-12. doi: 10.1080/10428194.2017.1280604.
    PubMed     Text format     Abstract available


  43. ZHOU G, Cao Y, Dong W, Lin Y, et al
    The clinical characteristics and prognostic significance of AID, miR-181b, and miR-155 expression in adult patients with de novo B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jan 31:1-12. doi: 10.1080/10428194.2017.1283028.
    PubMed     Text format     Abstract available


  44. CRAMPE M, Shakkak F, Kelly J, Hodgson A, et al
    Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Leuk Lymphoma. 2017 Jan 25:1-6. doi: 10.1080/10428194.2017.1281413.
    PubMed     Text format    


  45. HOLKOVA B, Yazbeck V, Kmieciak M, Bose P, et al
    A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Leuk Lymphoma. 2017 Jan 19:1-9. doi: 10.1080/10428194.2016.1276287.
    PubMed     Text format     Abstract available


  46. ALMAMUN M, Kholod O, Stuckel AJ, Levinson BT, et al
    Inferring a role for methylation of intergenic DNA in the regulation of genes aberrantly expressed in precursor B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jan 17:1-12. doi: 10.1080/10428194.2016.1272683.
    PubMed     Text format     Abstract available


  47. RAMACHANDRAN SS, Muiwo P, Ahmad HM, Pandey RM, et al
    miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jan 16:1. doi: 10.1080/10428194.2016.1272681.
    PubMed     Text format    


  48. EL-FATTAH MA
    Second malignancies in survivors of chronic myelomonocytic leukemia: a U.S. population-based study.
    Leuk Lymphoma. 2017 Jan 16:1-7. doi: 10.1080/10428194.2016.1276289.
    PubMed     Text format    


  49. YAN JS, Li YD, Liu SH, Yin QQ, et al
    The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.
    Leuk Lymphoma. 2017 Jan 16:1-7. doi: 10.1080/10428194.2016.1272690.
    PubMed     Text format    


  50. ESKAZAN AE
    Do all patients with chronic myeloid leukemia need to receive interferon during pregnancy?
    Leuk Lymphoma. 2017 Jan 16:1-5. doi: 10.1080/10428194.2016.1272685.
    PubMed     Text format    


  51. GUO Y, Strickland SA, Mohan S, Li S, et al
    MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jan 13:1-15. doi: 10.1080/10428194.2016.1272680.
    PubMed     Text format     Abstract available


  52. PETERSON LF, Lo MC, Liu Y, Gianolla D, et al
    Induction of p53 suppresses chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jan 13:1-14. doi: 10.1080/10428194.2016.1272682.
    PubMed     Text format     Abstract available


    December 2016
  53. SUMI M, Sato K, Kaiume H, Takeda W, et al
    Second cord blood transplantation and interferon-alpha maintenance therapy for relapsed Ph+ acute lymphoblastic leukemia with the T315I mutation.
    Leuk Lymphoma. 2016 Dec 21:1-3. doi: 10.1080/10428194.2016.1266623.
    PubMed     Text format    


  54. XIA X, Duan Y, Cui J, Jiang J, et al
    Association of methylenetetrahydrofolate reductase gene-gene interaction and haplotype with susceptibility to acute lymphoblastic leukemia in Chinese children.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  55. ZHANG L, McGraw KL, Sallman DA, List AF, et al
    The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  56. KUILA N, Nayak KB, Halder A, Agatheeswaran S, et al
    Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  57. GIRIDHAR KV, Shanafelt T, Tosh PK, Parikh SA, et al
    Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  58. YAN H, Zhang DY, Li X, Yuan XQ, et al
    Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  59. KENG MB, Keng HC, Tan BH, Wong GC, et al
    High risk of invasive fungal infections in adult acute lymphoblastic leukemia patients receiving induction and salvage chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  60. YEKTAEI-KARIN E, Zovko A, Nilsson A, Nasman-Glaser B, et al
    Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  61. SAVASOGLU K, Payzin KB, Ozdemirkiran F, Subasioglu A, et al
    The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  62. VINHAS R, Cordeiro M, Pedrosa P, Fernandes AR, et al
    Current trends in molecular diagnostics of chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  63. SHANMUGAM V, Dorfman DM
    An unusual case of chronic lymphocytic leukemia/small lymphocytic lymphoma with nodular morphology.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  64. VAN DE REE-PELLIKAAN C, van der Straten L, Riedl JA, Levin MD, et al
    High coincidence of chronic lymphocytic leukemia and myeloproliferative neoplasms: detection bias or a clue to a common pathophysiological path?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  65. VEY N, Prebet T, Thalamas C, Charbonnier A, et al
    Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  66. PESSINA C, Basilico C, Genoni A, Meroni E, et al
    A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    November 2016
  67. KOMMERS IO, Bartley PA, Budgen B, Latham S, et al
    Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  68. ASKLID A, Winqvist M, Eketorp Sylvan S, Mattsson A, et al
    Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  69. ORLANDI EM, Elena C, Bono E
    Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  70. SHANAFELT TD, Parikh SA, Noseworthy PA, Goede V, et al
    Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  71. GURU MURTHY GS, Dhakal I, Mehta P
    Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  72. MAURO FR, Carella AM, Molica S, Paoloni F, et al
    Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  73. MOLICA S, Giannarelli D, Levato L, Mirabelli R, et al
    Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI).
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  74. PAN J, Zhang Y, Zhao YL, Yang JF, et al
    Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  75. COMA M, Tothova E, Guman T, Hajikova M, et al
    Altered expression pattern of SLAM family receptors on pathological B cells of patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  76. BALASUBRAMANIAN P, Chopra A, Verma D, Singh IK, et al
    Imatinib resistance in chronic myeloid leukemia due to a rare mutation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  77. YAP KL, Furtado LV, Kiyotani K, Curran E, et al
    Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  78. HUSSAINI MO, Rehman A, Chavez JC, Pinilla-Ibarz J, et al
    EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  79. MIR R, Najar IA, Guru S, Javaid J, et al
    A deletion polymorphism in the RIZ gene is associated with increased progression of imatinib treated chronic myeloid leukemia patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  80. NAUMANN JA, Gordon PM
    In vitro model of leukemia cell migration across the blood-cerebrospinal fluid barrier.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  81. FINNES HD, Chaffee KG, Call TG, Ding W, et al
    Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  82. VAN DEN NESTE E
    Chronic lymphocytic leukemia management in the elderly: let us not forget the patient - even on a busy day.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  83. MINA R, D'Agostino M, Cerrato C, Gay F, et al
    Plasma cell leukemia: update on biology and therapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  84. DURANI U, Go RS
    Racial and ethnic disparities in the survival of adolescents and young adults with acute myeloid leukemia: a retrospective study using the US National Cancer Data Base.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  85. ROSSI D, Gerber B, Stussi G
    Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    October 2016
  86. PHILLIPS AA
    Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  87. YANG W, Tran P, Khan Z, Rezk S, et al
    MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  88. BRAUN M, Pastorczak A, Fendler W, Madzio J, et al
    Biallelic loss of CDKN2A is associated with poor response to treatment in pediatric acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  89. CRASSINI K, Shen Y, Mulligan S, Giles Best O, et al
    Modeling the chronic lymphocytic leukemia microenvironment in vitro.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  90. GOLDSCHMIDT N, Rund D
    Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  91. SEFTEL MD, Kuruvilla J, Kouroukis T, Banerji V, et al
    The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  92. POOLE A, Girard N, Clayton F, Tantravahi SK, et al
    Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  93. BRENNER AK, Aasebo E, Hernandez-Valladares M, Selheim F, et al
    Rethinking the role of osteopontin in human acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  94. DE LUCA L, D'Arena G, Simeon V, Trino S, et al
    Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  95. ZAHID MF, Lasho TL, Finke C, Ketterling RP, et al
    Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  96. SEYMOUR JF, Dohner H, Minden MD, Stone R, et al
    Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  97. GAO N, Yu WZ, Guo NJ, Wang XX, et al
    Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  98. NAKASE K, Kita K, Kyo T, Katayama N, et al
    High expression of interleukin-2 receptor alpha-chain (CD25) in myelodysplastic syndrome preceding acute myeloid leukemia and chronic myeloid leukemia in myeloid blast crisis.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  99. BENADIBA J, Rosilio C, Nebout M, Heimeroth V, et al
    Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  100. LITWINSKA Z, Machalinski B
    miRNAs in chronic myeloid leukemia: small molecules, essential function.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  101. FRIDLE C, Medinger M, Wilk MC, Seipel K, et al
    Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  102. WANG W, Foerner E, Buss E, Jauch A, et al
    Hematopoietic stem cells can be separated from leukemic cells in a subgroup of adult acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  103. BOHN JP, Wanner D, Steurer M
    Ibrutinib for relapsed refractory hairy cell leukemia variant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  104. ZHAO XS, Qin YZ, Liu YR, Chang YJ, et al
    The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  105. QIN YZ, Jiang Q, Lai YY, Jiang H, et al
    Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  106. KOKA R, Mainor CB, Banerjee A, Baer MR, et al
    Concomitant amplification of the MLL gene on a ring chromosome and a homogeneously staining region (hsr) in acute myeloid leukemia: mechanistic implications.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  107. PELED JU, Jenq RR
    Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  108. ROBAK T, Warzocha K, Govind Babu K, Kulyaba Y, et al
    Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  109. MORITA K, Nakamura F, Sakuishi K, Yamamoto T, et al
    Successful management of chronic myeloid leukemia with a complication of anti-SRP antibody-associated myopathy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  110. ZHANG W, Yang Y, Xie L, Ye Y, et al
    The first case of acute T-cell lymphoblastic leukemia containing the e19a2 BCR-ABL1 transcript: a durable molecular response using imatinib-based chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  111. YANADA M, Yano S, Kanamori H, Gotoh M, et al
    Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  112. YOSHIDA S, Tuscano E, Duong C, Chung J, et al
    Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  113. MEGIAS-VERICAT JE, Montesinos P, Herrero MJ, Moscardo F, et al
    Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    September 2016
  114. MEDINA D, David K, Lin Y, Schaar D, et al
    Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  115. MAITI A, Cortes JE, Brown YD, Kantarjian HM, et al
    Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  116. LI H, Zhang W, Yi D, Ye Y, et al
    Screening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  117. TESTI AM, Moleti ML, Canichella M, Mohamed S, et al
    Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  118. TOKUNAGA M, Uto H, Takeuchi S, Nakano N, et al
    Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  119. VALLIPURAM J, Dhalla S, Bell CM, Dresser L, et al
    Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    August 2016
  120. FARHADFAR N, Cerquozzi S, Hessenauer MR, Litzow MR, et al
    Acute leukemia in pregnancy: a single institution experience with 23 patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  121. KLIMAN D, Barnett M, Broady R, Forrest D, et al
    Comparison of a pediatric-inspired treatment protocol versusstandard-intensity chemotherapy for young adults with standard-riskBCR-ABL negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  122. WIERZBOWSKA A, Wawrzyniak E, Siemieniuk-Rys M, Kotkowska A, et al
    Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype - retrospective analysis of Polish Adult Leukemia Group (PALG).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  123. MARTIN-TREJO JA, Nunez-Enriquez JC, Fajardo-Gutierrez A, Medina-Sanson A, et al
    Early mortality in children with acute lymphoblastic leukemia in a developing country: the role of malnutrition at diagnosis. A multicenter cohort MIGICCL study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  124. TCHENG M, Samudio I, Lee EA, Minden MD, et al
    The mitochondria target drug avocatin B synergizes with induction chemotherapeutics to induce leukemia cell death.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  125. SORA F, Ponziani FR, Laurenti L, Chiusolo P, et al
    Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  126. BURKE MJ, Rheingold SR
    Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  127. XU Y, Wertheim G, Morrissette JJ, Bagg A, et al
    BRAF kinase domain mutations in de novo acute myeloid leukemia with monocytic differentiation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  128. MEYER-PANNWITT V, Steinbrecher D, Stilgenbauer S, Mertens D, et al
    Rapid detection of ATM/p53 function with p27Kip FACS analysis: a novel diagnostic tool for chronic lympocytic leukemia?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  129. VERGER E, Rattarittamrong E, Letort G, Raffoux E, et al
    Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  130. MCGOVERN B, Quinn F, Andrews C, Jeffers M, et al
    NOTCH1 mutation in type II Hodgkin transformation of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  131. LEE CJ, Shiraz P, Muffly L
    Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  132. CALDEMEYER L, Akard LP
    Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  133. GEMENETZI K, Galigalidou C, Vlachonikola E, Stalika E, et al
    Tp53 gene p72R polymorphism in chronic lymphocytic leukemia: incidence and clinical significance amongst cases with unmutated immunoglobulin receptors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  134. MOSAAD YM, Elashery R, Darwish A, Sharaf Eldein OA, et al
    GATA3 rs3824662 gene polymorphism as possible risk factor in a cohort of Egyptian patients with pediatric acute lymphoblastic leukemia and its prognostic impact.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  135. LOZANO-SANTOS C, Garcia-Vela JA, Perez-Sanz N, Nova-Gurumeta S, et al
    Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naive chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  136. JEZISKOVA I, Semerad L, Dvorakova D, Janeckova V, et al
    Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  137. VOJDEMAN FJ, Van't Veer MB, Tjonnfjord GE, Ittala-Remes M, et al
    The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    July 2016
  138. DE BRAEKELEER M, Douet-Guilbert N, De Braekeleer E
    Prognostic impact of p15 gene aberrations in acute leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  139. BACHANOVA V
    Deferring allogeneic transplantation for adult acute lymphoblastic leukemia: is there a second chance?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  140. MARIETTE C, Tavernier E, Hocquet D, Huynh A, et al
    Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  141. VATEL O, Aumont C, Mathy V, Petit M, et al
    Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  142. LAW AD, Dong Hwan Kim D, Lipton JH
    Pregnancy: part of life in chronic myelogenous leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  143. YIN Y, Li J, Yan W, Cheng Z, et al
    CEBPA mutation in a case of chronic myeloid leukemia presenting in myeloid blast crisis.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  144. PETTIT K, Stock W, Walter RB
    Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
    Leuk Lymphoma. 2016;57:1527-33.
    PubMed     Text format     Abstract available


    June 2016
  145. KUTSCH N, Busch R, Bahlo J, Mayer J, et al
    FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  146. ZHANG ZX, Shen CF, Shou LH, Fang Q, et al
    IRF-3 gene polymorphisms are associated with the susceptibility to and the survival in chronic lymphocytic leukemia and could also serve as an auxiliary index.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  147. BOMMANNAN K, Totadri S, Sachdeva MU, Naseem S, et al
    p210 BCR-ABL1 positive pediatric B-lineage acute lymphoblastic leukemia presenting with hypercalcemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  148. GUPTA SK, Bakhshi S, Kumar L, Kamal VK, et al
    Gene copy number alteration profile and its clinical correlation in B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  149. RASKOVA KAFKOVA L, Navrkalova V, Jarosova M, Loja T, et al
    Ability to downregulate the level of cyclin-dependent kinase inhibitor p27 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  150. KENEALY M, Patton N, Filshie R, Nicol A, et al
    Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  151. BEAUVERD Y, Cortes B, Masouye I, Chalandon Y, et al
    Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  152. YAMAZAKI E, Kanamori H, Itabashi M, Ogusa E, et al
    Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  153. DRENBERG CD, Buelow DR, Pounds SB, Wang YD, et al
    Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    May 2016
  154. MICHALLET M, Sobh M, Labussiere H, Lombard C, et al
    Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  155. MASON EF, Brown RD, Szeto DP, Gibson CJ, et al
    Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  156. ITONAGA H, Taguchi J, Taguchi M, Taniguchi H, et al
    Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  157. GAO YJ, Guo Y, Hu SY, Zhu YP, et al
    Philadelphia chromosome-positive acute lymphoblastic leukemia in China: a retrospective study from the Chinese Childhood Cancer Group.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  158. KAY NE, Sassoon T, Secreto C, Sinha S, et al
    Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  159. CHIEW MY, Boo NY, Voon K, Cheong SK, et al
    Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  160. PLESINGEROVA H, Librova Z, Plevova K, Libra A, et al
    COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available



  161. Wang, S.-Y., Chen, W.-L., Wang, Z.-C., et al. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia. Leuk. Lymphoma 2016. http://dx.doi.org/10.3109/10428194.2016.1160087.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  162. KATSUSHIMA H, Fukuhara N, Ichikawa S, Ota Y, et al
    Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi Prefecture.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  163. GRAIN A, Sirvent A, Strullu M, Francoise M, et al
    Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bo
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  164. HEIBLIG M, Le Jeune C, Elhamri M, Balsat M, et al
    Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  165. FANG Q, Zhao X, Li Q, Li Y, et al
    IKZF1 alterations and expression of CRLF2 predict prognosis in adult Chinese patients with B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available



  166. Jun Ji, Dr Li Zhang, Yuan-Yuan Wu, Xiao-Yu Zhu, Su-Qing Lv, Xi-Zuo Sun, Induction of apoptosis by d-limonene is mediated by a caspase-dependent mitochondrial death pathway in human leukemia cells. December 2006;47(12):2617-2624. http://dx.doi.org/10.1
    Leuk Lymphoma. 2016;57:1242.
    PubMed     Text format    


  167. CRAMER P, Langerbeins P, Fischer K, Eichhorst B, et al
    Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?
    Leuk Lymphoma. 2016;57:987-90.
    PubMed     Text format    


  168. GOEBELER ME, Bargou R
    Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Leuk Lymphoma. 2016;57:1021-32.
    PubMed     Text format     Abstract available


  169. HORNER TJ, Williams VC, Giampietro P, Witman PA, et al
    Long-term follow-up of previously treated and treatment-naive patients who received tositumomab and I-131 tositumomab.
    Leuk Lymphoma. 2016;57:1238-40.
    PubMed     Text format    


    April 2016
  170. MOTLLO C, Ribera JM, Morgades M, Granada I, et al
    Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  171. CHEN L, Wu Y, You Y, Xiao M, et al
    A novel e8a2 BCR-ABL1 intronic fusion through insertion of a chromosome 22 BCR gene fragment into chromosome 9 in an atypical Philadelphia (Ph) chromosome chronic myeloid leukemia patient.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  172. MCDOWELL MM, Zhu X, Agarwal N, Nikiforova MN, et al
    Response of relapsed central nervous system hairy cell leukemia to vemurafenib.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  173. LI J, Best OG, Mulligan SP, Fernando SL, et al
    Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  174. TANG Y, Wei X, Chen J, Du Y, et al
    Absolute quantification of BCR-ABL1 fusion transcripts in pediatric chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  175. MCGREGOR AK, Moulton D, Bown N, Cuthbert G, et al
    The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia - Response to Rashidi et al.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  176. IVANOV OFVERHOLM I, Tran AN, Olsson L, Zachariadis V, et al
    Detailed gene dose analysis reveals recurrent focal gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  177. FARRELL K, Fyfe A, Allan J, Tait RC, et al
    An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  178. TURHAN AG
    Reversible skin telangiectasia induced by imatinib mesylate in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  179. FENG J, Zhang W, Wu J, Gao S, et al
    Effect of initial absolute monocyte count on survival outcome of patients with de novo non-M3 acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  180. DENU RA, Lobo RH, Mattison RJ
    Management of differentiation syndrome in an elderly patient with acute promyelocytic leukemia who subsequently developed refractory anemia with ring sideroblasts.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  181. CRUZ NG, Ribeiro AF, Gloria AB, Abbas S, et al
    Characterization of NPM1, FLT3, and IDH1 mutations in adult patients with acute myeloid leukemia: a Brazilian cohort study.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  182. WANG SY, Chen WL, Wang ZC, Li XF, et al
    High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  183. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: molecularly contaminated, but not defined.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  184. SU L, Fei Y, Wei X, Guo J, et al
    Associations of parental occupational exposure to extremely low-frequency magnetic fields with childhood leukemia risk.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  185. CHEN LS, Yang JY, Liang H, Cortes JE, et al
    Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    March 2016
  186. RASHIDI A, Wolach O, El-Jawahri A, Ho VT, et al
    The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  187. CASSADAY RD, Alan Potts D Jr, Stevenson PA, Bar M, et al
    Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  188. DIRSE V, Gineikiene E, Zvirblis T, Bertasiute R, et al
    Single nucleotide polymorphism array analysis of clonal evolution in younger adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  189. CAVAZZINI F, Lista E, Quaglia FM, Formigaro L, et al
    Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  190. PATKAR N, Ghodke K, Joshi S, Chaudhary S, et al
    Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  191. VIDAL L, Gurion R, Ram R, Raanani P, et al
    Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  192. BELTON A, Xian L, Huso T, Koo M, et al
    STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.
    Leuk Lymphoma. 2016.
    PubMed     Text format    



  193. Peihua Luo, Meili Lin, Meihua Lin, Yiyu Chen, Bo Yang, Qiaojun He, Function of retinoid acid receptor a and p21 in all-trans-retinoic acid-induced acute T-lymphoblastic leukemia apoptosis. July 2009;50(7):1183-1189. http://dx/doi.org/10.1080/104281909
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  194. NICOLATO A, Nouer SA, Garnica M, Portugal R, et al
    Invasive fungal diseases in patients with acute lymphoid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available



  195. Wei Zhang, Bao-an Chen, Jun-fei Jin, You-ji He, and Yi-qi Niu, Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine. November 2013;54(11):2506-2516. http://dx.doi.org/10.31
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  196. DESHPANDE PA, Srivastava VM, Mani S, Anandhan S, et al
    Atypical BCR-ABL1 fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  197. RANI L, Mathur N, Gogia A, Vishnubhatla S, et al
    Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    February 2016
  198. YAMAMOTO C, Ito S, Mashima K, Umino K, et al
    Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  199. SCHLIEMANN I, Oschlies I, Nagel I, Maria Murga Penas E, et al
    The t(11;14)(q13;q32)/CCND1-IGH translocation is a recurrent secondary genetic aberration in relapsed chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  200. AL-DARWISH M, Farhan N, Al-Jebreen A, Allam R, et al
    The contribution of multiple packed red blood cell transfusions toward cardiac and liver dysfunction in pediatric patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  201. ABEDIN S, Platanias LC
    Whole-exome sequencing for relapse prediction in patients discontinuing TKI treatment in chronic myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  202. BORGE M, Delpino MV, Podaza E, Stanganelli C, et al
    Soluble RANKL production by leukemic cells in a case of chronic lymphocytic leukemia with bone destruction.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  203. DEBOER R, Koval G, Mulkey F, Wetzler M, et al
    Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  204. ASSAL A, Dong B, Khan H, Medavarapu R, et al
    Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  205. WANQUET A, Crocchiolo R, Furst S, Granata A, et al
    The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk mye
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  206. STYCZYNSKI J, Czyzewski K, Wysocki M, Zajac-Spychala O, et al
    Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  207. DRACHTMAN RA, Masterson M, Shenkerman A, Vijayanathan V, et al
    Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on The Cancer Institute of New Jersey ALL trial (CINJALL).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  208. KUANG P, Liu T, Pan L, Zhu H, et al
    Sustaining integrating imatinib and interferon-alpha into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  209. ELBAEK MV, Sorensen AL, Hasselbalch HC
    Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  210. VIGNA E, Gentile M, Giagnuolo G, Recchia AG, et al
    Long-term molecular remission in Philadelphia-positive acute lymphoblastic leukemia elderly patient after dasatinib discontinuation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  211. SAJAROFF EO, Mansini A, Rubio P, Alonso CN, et al
    B-cell acute lymphoblastic leukemia with mature phenotype and MLL rearrangement: report of five new cases and review of the literature.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  212. KO BW, Han J, Heo JY, Jang Y, et al
    Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  213. MAMEZ AC, Raffoux E, Chevret S, Lemiale V, et al
    Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  214. ANDERSEN MA, Vojdeman FJ, Andersen MK, Brown PN, et al
    Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    January 2016
  215. ORGEL E, Mueske NM, Sposto R, Gilsanz V, et al
    Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  216. KAPLAN JB, Altman JK, Platanias LC
    SNPing away to individualize induction therapy for acute myelogenous leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  217. WALKER AR, Wang H, Walsh K, Bhatnagar B, et al
    Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  218. OSTERBORG A, Udvardy M, Zaritskey A, Andersson PO, et al
    Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  219. MADDOCKS K, Hertlein E, Chen TL, Wagner AJ, et al
    A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  220. KAPELKO-SLOWIK K, Owczarek TB, Grzymajlo K, Urbaniak-Kujda D, et al
    Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  221. WENDTNER CM, Hallek M, Fraser GA, Michallet AS, et al
    Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  222. AYESH HAJ YOUSEF MH, Khassawneh B
    Granulocyte-colony stimulating factor induces disseminated intravascular coagulation in dormant acute promyelocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  223. HARA T, Matsumoto T, Shibata Y, Nakamura N, et al
    Prognostic value of the combination of serum l-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  224. SMIRNIKHINA SA, Lavrov AV, Chelysheva EY, Adilgereeva EP, et al
    Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  225. KATKISH L, Rector T, Ishani A, Gupta P, et al
    Incidence and severity of pseudohyperkalemia in chronic lymphocytic leukemia: a longitudinal analysis.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  226. GODWIN CD, Othus M, Powell MA, Buckley SA, et al
    Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  227. TANTRAVAHI SK, Szankasi P, Khorashad JS, Dao KH, et al
    A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza(R)) in Patients with Chronic Myelomonocytic Leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  228. LEE MH, Kim SY
    Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  229. RIZZIERI DA, Cooley S, Odenike O, Moonan L, et al
    An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  230. FELICE MS, Rossi JG, Alonso CN, Gallego MS, et al
    Experience with four consecutive BFM-based protocols for treatment of childhood with non-promyelocytic acute myeloblastic leukemia in Argentina.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  231. TAM CS, Polliack A
    Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  232. HEDLEY D, Shamas-Din A, Chow S, Sanfelice D, et al
    A Phase I Study of Elesclomol Sodium in Patients with Acute Myeloid Leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  233. ROTIN LE, Gronda M, Hurren R, Wang XM, et al
    Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  234. MILLER TP, Getz KD, Kavcic M, Li Y, et al
    A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  235. NIWA Y, Minami Y, Abe A, Hayakawa F, et al
    Wnt signaling is associated with cell survival in the interaction between acute myeloid leukemia cells and stromal cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  236. AKARD LP, Bixby D
    Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  237. LU BY, Thanawala SU, Zochowski KC, Carroll WL, et al
    Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  238. ZENT CS
    Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  239. SANFORD D, Garcia-Manero G, Jorgensen J, Konoplev S, et al
    CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  240. THOTA S, Sekeres MA
    Combination therapies for MDS and AML: Does one plus one equal one?
    Leuk Lymphoma. 2016;57:505-6.
    PubMed     Text format    


  241. CARDONA ME, Simonson OE, Oprea II, Moreno PM, et al
    A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.
    Leuk Lymphoma. 2016;57:183-92.
    PubMed     Text format     Abstract available


  242. RIVA E, Manrique Arechavaleta G, De Almeida C, Costa V, et al
    A novel e8a2 BCR-ABL1 fusion with insertion of MAST2 exon 2 in a four-way translocation t (1;17;9;22) (p35;q24;q44;q11) in a patient with chronic myeloid leukemia.
    Leuk Lymphoma. 2016;57:203-5.
    PubMed     Text format    


  243. LIPOWSKA-BHALLA G, Fagnano E, Illidge TM, Cheadle EJ, et al
    Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
    Leuk Lymphoma. 2016;57:1269-80.
    PubMed     Text format     Abstract available


  244. GORNIAK P, Budziszewska B, Pula B, Wasylecka M, et al
    Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease.
    Leuk Lymphoma. 2016;57:1471-3.
    PubMed     Text format    


  245. MICHALLET AS, Sesques P, Rabe KG, Itti E, et al
    An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter's Syndrome.
    Leuk Lymphoma. 2016;57:1474-7.
    PubMed     Text format    


  246. YE XN, Zhou XP, Wei JY, Xu GX, et al
    Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Leuk Lymphoma. 2016;57:1311-8.
    PubMed     Text format     Abstract available


    December 2015
  247. JAIN P, Verstovsek S, Wang W, Loghavi S, et al
    DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  248. GARG S, Shanmukhaiah C, Ghosh K, Madkaikar M, et al
    Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  249. CALLEA M, Bellacchio E, Fattori F, Bertini E, et al
    Acute myeloid leukemia in a 3 years old child with cleidocranial dysplasia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  250. ZENT CS, Bowen DA, Conte MJ, LaPlant BR, et al
    Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  251. SUN C, Wiestner A
    Under the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  252. ARAKI D, Othus M, Walter RB, Becker PS, et al
    Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  253. BROGILE L, Hijiya N, Helenowski IB, Dilley K, et al
    Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  254. TSURUSAWA M, Watanabe T, Gosho M, Mori T, et al
    Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  255. BABUSHOK DV, Bessler M, Olson TS
    Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  256. ZHENG C, Zhu X, Tang B, Zhang L, et al
    The impact of pre-transplantation minimal residual disease on outcome of intensified myeloablative cord blood transplantation for acute myeloid leukemia in first or second complete remission.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  257. SHI M, Neff JL, Jevremovic D, Morice WG, et al
    Decreased normal NK-cells is a characteristic of T-cell large granular lymphocytic leukemia and is strongly associated with cytopenia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    



  258. Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk lymphoma 2015 nov 16. [epub ahead of print]. http://dx.doi.org/10.3109/10428194.2015.1094692.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  259. NOH H, Park MS, Kim SH, Oh SJ, et al
    Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  260. MCGREGOR AK, Moulton D, Bown N, Cuthbert G, et al
    Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  261. ROZOVSKI U, Hazan-Halevy I, Barzilai M, Keating MJ, et al
    Metabolism pathways in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


    November 2015
  262. PAREKH V, Peker D
    Clinicopathologic and cytogenetic characterization of therapy-related acute T lymphoblastic leukemia in adult population.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  263. MULLER D, Fischer K, Kaiser P, Eichhorst B, et al
    Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


    October 2015
  264. WARTMAN LD, Fiala MA, Fletcher T, Hawkins ER, et al
    A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


    May 2015
  265. PALACIOS F, Prieto D, Abreu C, Ruiz S, et al
    Dissecting chronic lymphocytic leukemia microenvironment signals in patients with unmutated disease: microRNA-22 regulates phosphatase and tensin homolog/AKT/FOXO1 pathway in proliferative leukemic cells.
    Leuk Lymphoma. 2015;56:1560-5.
    PubMed     Text format     Abstract available


  266. SHIN SY, Lee ST, Kim HJ, Jang JH, et al
    A case of CD5-positive mature B-cell neoplasm with t(10;14)(q24;q11.2) and trisomy 12.
    Leuk Lymphoma. 2015;56:1550-1.
    PubMed     Text format    


  267. TESTA U, Pelosi E
    MicroRNAs expressed in hematopoietic stem/progenitor cells are deregulated in acute myeloid leukemias.
    Leuk Lymphoma. 2015;56:1466-74.
    PubMed     Text format     Abstract available


  268. TIAN H, Chen GH, Xu Y, Ma X, et al
    Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study.
    Leuk Lymphoma. 2015;56:1353-61.
    PubMed     Text format     Abstract available


  269. OHM L, Lundqvist A, Dickman P, Hoglund M, et al
    Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
    Leuk Lymphoma. 2015;56:1385-91.
    PubMed     Text format     Abstract available


  270. WASIK AM, Priebe V, Lord M, Jeppsson-Ahlberg A, et al
    Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma.
    Leuk Lymphoma. 2015;56:1425-31.
    PubMed     Text format     Abstract available


  271. ZHU L, Wang Z, Zheng X, Ding L, et al
    Haploidentical hematopoietic stem cell transplant with umbilical cord-derived multipotent mesenchymal cell infusion for the treatment of high-risk acute leukemia in children.
    Leuk Lymphoma. 2015;56:1346-52.
    PubMed     Text format     Abstract available


  272. ROY MOULIK N, Kumar A, Agrawal S, Awasthi S, et al
    Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2015;56:1379-84.
    PubMed     Text format     Abstract available


    March 2015
  273. FILANOVSKY K, Yacobi R, Vorst E, Barshack I, et al
    Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.
    Leuk Lymphoma. 2015;56:823-5.
    PubMed     Text format    


  274. PATEL AB, Chen YH, Zhang Y, Frankfurt O, et al
    Achievement of morphologic and cytogenetic remission with single-agent hydroxyurea in a patient with acute myeloid leukemia with inv(16).
    Leuk Lymphoma. 2015;56:817-9.
    PubMed     Text format    


  275. BARTRAM T, Burkhardt B, Wossmann W, Seidemann K, et al
    Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Munster Study Group.
    Leuk Lymphoma. 2015;56:814-6.
    PubMed     Text format    


  276. YAO C, Du W, Chen H, Xiao S, et al
    The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
    Leuk Lymphoma. 2015;56:755-62.
    PubMed     Text format     Abstract available


  277. COCCARO N, Tota G, Anelli L, Zagaria A, et al
    Centromeric fragment of chromosome 7 in atypical chronic myeloid leukemia with the SET binding protein 1 gene mutation.
    Leuk Lymphoma. 2015;56:826-8.
    PubMed     Text format    


  278. BIGLIARDI S, Morselli M, Potenza L, Coluccio V, et al
    Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study.
    Leuk Lymphoma. 2015;56:770-3.
    PubMed     Text format    


  279. YOSHIDA M, Tamagawa N, Nakao T, Kanashima H, et al
    Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.
    Leuk Lymphoma. 2015;56:768-9.
    PubMed     Text format    


  280. ESTEPHAN F, Rogers HJ, Visconte V, Tabarroki A, et al
    Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia.
    Leuk Lymphoma. 2015;56:811-3.
    PubMed     Text format    


  281. JAMROZIAK K, Szemraj J, Robak T, Tukiendorf A, et al
    Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen.
    Leuk Lymphoma. 2015;56:808-10.
    PubMed     Text format    


  282. POON ML, Fox PS, Samuels BI, O'Brien S, et al
    Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.
    Leuk Lymphoma. 2015;56:711-5.
    PubMed     Text format     Abstract available


  283. MULAY S, Boruchov A
    Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab.
    Leuk Lymphoma. 2015;56:805-7.
    PubMed     Text format    


  284. GE Y, Yang B, Xu X, Dai Q, et al
    Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Leuk Lymphoma. 2015;56:730-8.
    PubMed     Text format     Abstract available


  285. KRUMBHOLZ M, Jung R, Bradtke J, Reinhardt D, et al
    Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific MLL-FNBP1 fusion gene.
    Leuk Lymphoma. 2015;56:793-6.
    PubMed     Text format    


  286. MANT S, Taylor G, Dutton D, Butler A, et al
    Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic lymphocytic leukemia: a series of six cases.
    Leuk Lymphoma. 2015;56:774-8.
    PubMed     Text format    


  287. UEDA M, Xie H, Sandhu RK, Walter RB, et al
    Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia.
    Leuk Lymphoma. 2015;56:782-4.
    PubMed     Text format    


  288. TAM CS, Stilgenbauer S
    How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Leuk Lymphoma. 2015;56:587-93.
    PubMed     Text format     Abstract available


  289. SCHMIDT C, Fingerle-Rowson G, Boehme A, Brendel K, et al
    Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.
    Leuk Lymphoma. 2015;56:694-702.
    PubMed     Text format     Abstract available


  290. KU M, Wall M, MacKinnon RN, Walkley CR, et al
    Src family kinases and their role in hematological malignancies.
    Leuk Lymphoma. 2015;56:577-86.
    PubMed     Text format     Abstract available


  291. KHOURY HJ, Bixby DL
    Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
    Leuk Lymphoma. 2015;56:568-76.
    PubMed     Text format     Abstract available


  292. PLESA A, Elhamri M, Clapisson G, Mattei E, et al
    Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia.
    Leuk Lymphoma. 2015;56:622-9.
    PubMed     Text format     Abstract available


  293. PARASOLE R, Petruzziello F, Messina C, Barisone E, et al
    Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
    Leuk Lymphoma. 2015;56:650-5.
    PubMed     Text format     Abstract available


  294. LICKLITER JD, Taylor K, Szer J, Grigg A, et al
    An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.
    Leuk Lymphoma. 2015;56:630-8.
    PubMed     Text format     Abstract available


  295. GLITZA IC, Lu G, Shah R, Bashir Q, et al
    Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.
    Leuk Lymphoma. 2015;56:602-7.
    PubMed     Text format     Abstract available


    February 2015
  296. REISS J, Link B, Ruan J, Furman R, et al
    Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


    November 2014
  297. GIULINO-ROTH L
    EZH2: A potential new target in T-cell lymphoma?
    Leuk Lymphoma. 2014.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: